Sector News

Valeant completes sale of Dendreon to Sanpower for $819.9m

July 4, 2017
Life sciences

Canadian company Valeant Pharmaceuticals International has completed the sale of all outstanding equity interests in its subsidiary Dendreon Pharmaceuticals to the Sanpower Group for $819.9m.

Under the deal, Valeant Pharmaceuticals will use net proceeds from the sale to permanently repay term loan debt under its senior credit facility.

Upon closing the transaction, the company expects to pay down $5bn in debt from the sale proceeds and free cash-flow within 18 months after next month.

Valeant Pharmaceuticals International chairman and chief executive officer Joseph Papa said: “We continue to deliver on our commitments to reduce debt and simplify our portfolio, while focusing resources on our core businesses.

“The proceeds from this sale along with the recently announced sale of the iNova business move us closer to paying down $5bn of debt from divestitures and free cash-flow, and we are confident we will meet and potentially exceed this commitment.”

As estimated by Valeant, expected revenue and adjusted earnings before interest, tax, depreciation, and amortisation (EBITDA) (non-GAAP) from the Dendreon business in the second half of this year would have been $170m and $65m respectively.

In January, Valeant Pharmaceuticals’ affiliate entered a definitive agreement to sell the outstanding equity interests in Dendreon.

The first and only commercialised product of Dendreon Pharmaceuticals is Provenge, which is an autologous cellular immunotherapy (vaccine) for prostate cancer treatment.

Provenge received approval from the US Food and Drug Administration (FDA) in April 2010.

Source: Pharmaceutical Technology

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach